Biogen Idec Takes Option to MAKScientific MS Program

Biogen Idec Takes Option to MAKScientific MS Program

 

Boston, Mass., March 14, 2012.  MAKScientific, LLC, a privately held company focused on the discovery of novel therapeutics modulating cannabinoid pathways, today announced that is has entered into an exclusive, worldwide option and collaboration agreement with Biogen Idec (NASDAQ: BIIB) to develop and commercialize drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.

 

Under the agreement, Biogen Idec will receive an option for an exclusive license to select discovery-stage MAKScientific drug candidates for all indications worldwide.  Upon Biogen Idec's exercise of the option, MAKScientific will be eligible to receive an exercise fee of up to $3 million and up to an additional $31 million in milestone payments associated with the clinical development of the drug candidates.  In addition, MAKScientific will be eligible to receive royalties on net sales worldwide.

 

"We are very excited to initiate this collaboration with Biogen Idec," said Alexandros Makriyannis, PhD, Founder of MAKScientific.  "We believe it will help advance our proprietary medicinal chemistry to the benefit of MS patients.  As a global leader in MS research and development, Biogen Idec is the ideal partner for our discovery and development program."

 

About MAKScientific

 

MAKScientific, LLC, is a privately held, Massachusetts-based, discovery stage, life sciences company specializing in the identification and development of novel therapies exploiting cutting edge cannabinoid receptor pathways for the treatment of pain, inflammatory disorders and MS.

 

For full article, please click here

 

For more information please contact:

Harry Penner, Jr. Director, 203-676-3676  [email protected]

Alex Makriyannis, Ph.D., Founder, 617-319-9152              617-319-9152       [email protected]

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.